Canadian stroke best practice recommendations: Secondary prevention of stroke, sixth edition practice guidelines, update 2017

Theodore Wein; M. Patrice Lindsay; Robert Côté; Norine Foley; Joseph Berlingieri; Sanjit Bhogal; Aline Bourgoin; Brian H. Buck; Jafna Cox; Dion Davidson; Dar Dowlatshahi; Jim Douketis; John Falconer; Thalia Field; Laura Gioia; Gord Gubitz; Jeffrey Habert; Sharon Jaspers; Cheemun Lum; Dana McNamara Morse; Paul Pageau; Mubeen Rafay; Amanda Rodgerson; Bill Semchuk; Mukul Sharma; Ashkan Shoamanesh; Arturo Tamayo; Elisabeth Smitko; David J. Gladstone

doi:10.1177/1747493017743062

Canadian stroke best practice recommendations: Secondary prevention of stroke, sixth edition practice guidelines, update 2017

Theodore Wein, M. Patrice Lindsay, Robert Côté, Norine Foley, Joseph Berlingieri, Sanjit Bhogal, Aline Bourgoin, Brian H. Buck, Jafna Cox, Dion Davidson, Dar Dowlatshahi, Jim Douketis, John Falconer, Thalia Field, Laura Gioia, Gord Gubitz, Jeffrey Habert, Sharon Jaspers, Cheemun Lum, Dana McNamara MorsePaul Pageau, Mubeen Rafay, Amanda Rodgerson, Bill Semchuk, Mukul Sharma, Ashkan Shoamanesh, Arturo Tamayo, Elisabeth Smitko, David J. Gladstone

Medicine

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

182 Citas (Scopus)

Resumen

The 2017 update of The Canadian Stroke Best Practice Recommendations for the Secondary Prevention of Stroke is a collection of current evidence-based recommendations intended for use by clinicians across a wide range of settings. The goal is to provide guidance for the prevention of ischemic stroke recurrence through the identification and management of modifiable vascular risk factors. Recommendations include those related to diagnostic testing, diet and lifestyle, smoking, hypertension, hyperlipidemia, diabetes, antiplatelet and anticoagulant therapies, carotid artery disease, atrial fibrillation, and other cardiac conditions. Notable changes in this sixth edition include the development of core elements for delivering secondary stroke prevention services, the addition of a section on cervical artery dissection, new recommendations regarding the management of patent foramen ovale, and the removal of the recommendations on management of sleep apnea. The Canadian Stroke Best Practice Recommendations include a range of supporting materials such as implementation resources to facilitate the adoption of evidence to practice, and related performance measures to enable monitoring of uptake and effectiveness of the recommendations. The guidelines further emphasize the need for a systems approach to stroke care, involving an interprofessional team, with access to specialists regardless of patient location, and the need to overcome geographic barriers to ensure equity in access within a universal health care system.

Idioma original	English
Páginas (desde-hasta)	420-443
Número de páginas	24
Publicación	International Journal of Stroke
Volumen	13
N.º	4
DOI	https://doi.org/10.1177/1747493017743062
Estado	Published - jun. 1 2018

Nota bibliográfica

Funding Information:
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The following authors have identified actual or potential conflicts of interest which have been mitigated through the design of a multidisciplinary writing group model and additional measures by the advisory committee as required. Theodore Wein: researcher, speaker and travel reimbursement for Boehringer Ingelheim, Bayer, Allergan Inc., and Servier; David Gladstone: supported by a Mid-Career Award from the Heart & Stroke Foundation; no relationships with industry or other disclosures effective 1 July 2016 to present; previous disclosures (pre-2016): speaker fees for CME events and/or honoraria for advisory boards from Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Pfizer; PI of EMRACE and SCREEN-AF trials; Robert Côté: speaker bureau for Pfizer and Bristol Myers Squibb, Brian H Buck: speaker and advisory board member for Bayer; Jafna Cox: Funded research, speaker, advisory board member for Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Pfizer; Dar Dowlatshahi: speaker and/or advisory honoraria from Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, and Pfizer; Jim Douketis: Participant in Advisory Boards or Educational Activities for following companies: Bayer, Bristol-Myers-Squibb, Sanofi, Astra-Zeneca, Boehringer-Ingelheim, Pfizer, Biotie, Portola, The Medicines Co, Daiichi-Sankyo, and consultant to Actelion, AGEN Biomedical, Ortho-Janssen Pharmaceuticals, Boehringer-Ingelheim, Janssen Pharmaceuticals, Grant support from Boehringer-Ingelheim; Thalia Fields: Advisory Board and Speakers’ Bureau, research methodology training program participation for Bayer Canada and Bayer Global, and funded research from Boehringer Ingelheim; Laura Gioia: advisory board member for Bayer Canada and Bayer Global; Gord Gubitz: advisory board member for Bayer; Jeffrey Habert: advisory board member and speaker for Bayer, Bristol-Myers-Squibb, Boehringer-Ingelheim, Pfizer, Eli-Lilly, Astra-Zeneca, Janssen, Novo-Nordisk; Sharon Jaspers: speaker honorarium for Bayer, Boehringer Ingelheim, Pfizer; Bill Semchuk: speaker for Boehringer Ingelheim, Bayer and BMS Pfizer; Mukul Sharma: advisory board member and speaker for Bristol Myers Squibb, Bayer; Boehringer Ingelheim, AZ Therapies, Daiichi Sankyo; Ashkan Shoamanesh: Research Stipend for Ongoing Committee Involvement in the NAVIGATE ESUS trial by Bayer HealthCare Pharmaceuticals; Arturo Tamayo: Speaker for Bayer, Boehringer Ingelheim and Bristol-Myers Squibb. The following authors have no conflicts to declare: M Patrice Lindsay, Norine Foley, Joseph Berlingieri, Sanjit Bhogal, Aline Bourgoin, Dion Davidson, John Falconer, Cheemun Lum, Dana McNamara Morse, Paul Pageau, Mubeen Rafay, Amanda Rodgerson, Elisabeth Smitko.

Publisher Copyright:
© 2017, © 2017 World Stroke Organization.

ASJC Scopus Subject Areas

Neurology

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1177/1747493017743062

Otros archivos y enlaces

Citar esto

Wein, T., Lindsay, M. P., Côté, R., Foley, N., Berlingieri, J., Bhogal, S., Bourgoin, A., Buck, B. H., Cox, J., Davidson, D., Dowlatshahi, D., Douketis, J., Falconer, J., Field, T., Gioia, L., Gubitz, G., Habert, J., Jaspers, S., Lum, C., ... Gladstone, D. J. (2018). Canadian stroke best practice recommendations: Secondary prevention of stroke, sixth edition practice guidelines, update 2017. International Journal of Stroke, 13(4), 420-443. https://doi.org/10.1177/1747493017743062

Wein, T, Lindsay, MP, Côté, R, Foley, N, Berlingieri, J, Bhogal, S, Bourgoin, A, Buck, BH, Cox, J, Davidson, D, Dowlatshahi, D, Douketis, J, Falconer, J, Field, T, Gioia, L, Gubitz, G, Habert, J, Jaspers, S, Lum, C, McNamara Morse, D, Pageau, P, Rafay, M, Rodgerson, A, Semchuk, B, Sharma, M, Shoamanesh, A, Tamayo, A, Smitko, E & Gladstone, DJ 2018, 'Canadian stroke best practice recommendations: Secondary prevention of stroke, sixth edition practice guidelines, update 2017', International Journal of Stroke, vol. 13, n.º 4, pp. 420-443. https://doi.org/10.1177/1747493017743062

@article{53ee0249e2e447278f3f914b8ee49a6e,

title = "Canadian stroke best practice recommendations: Secondary prevention of stroke, sixth edition practice guidelines, update 2017",

abstract = "The 2017 update of The Canadian Stroke Best Practice Recommendations for the Secondary Prevention of Stroke is a collection of current evidence-based recommendations intended for use by clinicians across a wide range of settings. The goal is to provide guidance for the prevention of ischemic stroke recurrence through the identification and management of modifiable vascular risk factors. Recommendations include those related to diagnostic testing, diet and lifestyle, smoking, hypertension, hyperlipidemia, diabetes, antiplatelet and anticoagulant therapies, carotid artery disease, atrial fibrillation, and other cardiac conditions. Notable changes in this sixth edition include the development of core elements for delivering secondary stroke prevention services, the addition of a section on cervical artery dissection, new recommendations regarding the management of patent foramen ovale, and the removal of the recommendations on management of sleep apnea. The Canadian Stroke Best Practice Recommendations include a range of supporting materials such as implementation resources to facilitate the adoption of evidence to practice, and related performance measures to enable monitoring of uptake and effectiveness of the recommendations. The guidelines further emphasize the need for a systems approach to stroke care, involving an interprofessional team, with access to specialists regardless of patient location, and the need to overcome geographic barriers to ensure equity in access within a universal health care system.",

author = "Theodore Wein and Lindsay, {M. Patrice} and Robert C{\^o}t{\'e} and Norine Foley and Joseph Berlingieri and Sanjit Bhogal and Aline Bourgoin and Buck, {Brian H.} and Jafna Cox and Dion Davidson and Dar Dowlatshahi and Jim Douketis and John Falconer and Thalia Field and Laura Gioia and Gord Gubitz and Jeffrey Habert and Sharon Jaspers and Cheemun Lum and {McNamara Morse}, Dana and Paul Pageau and Mubeen Rafay and Amanda Rodgerson and Bill Semchuk and Mukul Sharma and Ashkan Shoamanesh and Arturo Tamayo and Elisabeth Smitko and Gladstone, {David J.}",

note = "Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The following authors have identified actual or potential conflicts of interest which have been mitigated through the design of a multidisciplinary writing group model and additional measures by the advisory committee as required. Theodore Wein: researcher, speaker and travel reimbursement for Boehringer Ingelheim, Bayer, Allergan Inc., and Servier; David Gladstone: supported by a Mid-Career Award from the Heart & Stroke Foundation; no relationships with industry or other disclosures effective 1 July 2016 to present; previous disclosures (pre-2016): speaker fees for CME events and/or honoraria for advisory boards from Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Pfizer; PI of EMRACE and SCREEN-AF trials; Robert C{\^o}t{\'e}: speaker bureau for Pfizer and Bristol Myers Squibb, Brian H Buck: speaker and advisory board member for Bayer; Jafna Cox: Funded research, speaker, advisory board member for Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Pfizer; Dar Dowlatshahi: speaker and/or advisory honoraria from Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, and Pfizer; Jim Douketis: Participant in Advisory Boards or Educational Activities for following companies: Bayer, Bristol-Myers-Squibb, Sanofi, Astra-Zeneca, Boehringer-Ingelheim, Pfizer, Biotie, Portola, The Medicines Co, Daiichi-Sankyo, and consultant to Actelion, AGEN Biomedical, Ortho-Janssen Pharmaceuticals, Boehringer-Ingelheim, Janssen Pharmaceuticals, Grant support from Boehringer-Ingelheim; Thalia Fields: Advisory Board and Speakers{\textquoteright} Bureau, research methodology training program participation for Bayer Canada and Bayer Global, and funded research from Boehringer Ingelheim; Laura Gioia: advisory board member for Bayer Canada and Bayer Global; Gord Gubitz: advisory board member for Bayer; Jeffrey Habert: advisory board member and speaker for Bayer, Bristol-Myers-Squibb, Boehringer-Ingelheim, Pfizer, Eli-Lilly, Astra-Zeneca, Janssen, Novo-Nordisk; Sharon Jaspers: speaker honorarium for Bayer, Boehringer Ingelheim, Pfizer; Bill Semchuk: speaker for Boehringer Ingelheim, Bayer and BMS Pfizer; Mukul Sharma: advisory board member and speaker for Bristol Myers Squibb, Bayer; Boehringer Ingelheim, AZ Therapies, Daiichi Sankyo; Ashkan Shoamanesh: Research Stipend for Ongoing Committee Involvement in the NAVIGATE ESUS trial by Bayer HealthCare Pharmaceuticals; Arturo Tamayo: Speaker for Bayer, Boehringer Ingelheim and Bristol-Myers Squibb. The following authors have no conflicts to declare: M Patrice Lindsay, Norine Foley, Joseph Berlingieri, Sanjit Bhogal, Aline Bourgoin, Dion Davidson, John Falconer, Cheemun Lum, Dana McNamara Morse, Paul Pageau, Mubeen Rafay, Amanda Rodgerson, Elisabeth Smitko. Publisher Copyright: {\textcopyright} 2017, {\textcopyright} 2017 World Stroke Organization.",

year = "2018",

month = jun,

day = "1",

doi = "10.1177/1747493017743062",

language = "English",

volume = "13",

pages = "420--443",

journal = "International Journal of Stroke",

issn = "1747-4930",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Canadian stroke best practice recommendations

T2 - Secondary prevention of stroke, sixth edition practice guidelines, update 2017

AU - Wein, Theodore

AU - Lindsay, M. Patrice

AU - Côté, Robert

AU - Foley, Norine

AU - Berlingieri, Joseph

AU - Bhogal, Sanjit

AU - Bourgoin, Aline

AU - Buck, Brian H.

AU - Cox, Jafna

AU - Davidson, Dion

AU - Dowlatshahi, Dar

AU - Douketis, Jim

AU - Falconer, John

AU - Field, Thalia

AU - Gioia, Laura

AU - Gubitz, Gord

AU - Habert, Jeffrey

AU - Jaspers, Sharon

AU - Lum, Cheemun

AU - McNamara Morse, Dana

AU - Pageau, Paul

AU - Rafay, Mubeen

AU - Rodgerson, Amanda

AU - Semchuk, Bill

AU - Sharma, Mukul

AU - Shoamanesh, Ashkan

AU - Tamayo, Arturo

AU - Smitko, Elisabeth

AU - Gladstone, David J.

N1 - Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The following authors have identified actual or potential conflicts of interest which have been mitigated through the design of a multidisciplinary writing group model and additional measures by the advisory committee as required. Theodore Wein: researcher, speaker and travel reimbursement for Boehringer Ingelheim, Bayer, Allergan Inc., and Servier; David Gladstone: supported by a Mid-Career Award from the Heart & Stroke Foundation; no relationships with industry or other disclosures effective 1 July 2016 to present; previous disclosures (pre-2016): speaker fees for CME events and/or honoraria for advisory boards from Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Pfizer; PI of EMRACE and SCREEN-AF trials; Robert Côté: speaker bureau for Pfizer and Bristol Myers Squibb, Brian H Buck: speaker and advisory board member for Bayer; Jafna Cox: Funded research, speaker, advisory board member for Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Pfizer; Dar Dowlatshahi: speaker and/or advisory honoraria from Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, and Pfizer; Jim Douketis: Participant in Advisory Boards or Educational Activities for following companies: Bayer, Bristol-Myers-Squibb, Sanofi, Astra-Zeneca, Boehringer-Ingelheim, Pfizer, Biotie, Portola, The Medicines Co, Daiichi-Sankyo, and consultant to Actelion, AGEN Biomedical, Ortho-Janssen Pharmaceuticals, Boehringer-Ingelheim, Janssen Pharmaceuticals, Grant support from Boehringer-Ingelheim; Thalia Fields: Advisory Board and Speakers’ Bureau, research methodology training program participation for Bayer Canada and Bayer Global, and funded research from Boehringer Ingelheim; Laura Gioia: advisory board member for Bayer Canada and Bayer Global; Gord Gubitz: advisory board member for Bayer; Jeffrey Habert: advisory board member and speaker for Bayer, Bristol-Myers-Squibb, Boehringer-Ingelheim, Pfizer, Eli-Lilly, Astra-Zeneca, Janssen, Novo-Nordisk; Sharon Jaspers: speaker honorarium for Bayer, Boehringer Ingelheim, Pfizer; Bill Semchuk: speaker for Boehringer Ingelheim, Bayer and BMS Pfizer; Mukul Sharma: advisory board member and speaker for Bristol Myers Squibb, Bayer; Boehringer Ingelheim, AZ Therapies, Daiichi Sankyo; Ashkan Shoamanesh: Research Stipend for Ongoing Committee Involvement in the NAVIGATE ESUS trial by Bayer HealthCare Pharmaceuticals; Arturo Tamayo: Speaker for Bayer, Boehringer Ingelheim and Bristol-Myers Squibb. The following authors have no conflicts to declare: M Patrice Lindsay, Norine Foley, Joseph Berlingieri, Sanjit Bhogal, Aline Bourgoin, Dion Davidson, John Falconer, Cheemun Lum, Dana McNamara Morse, Paul Pageau, Mubeen Rafay, Amanda Rodgerson, Elisabeth Smitko. Publisher Copyright: © 2017, © 2017 World Stroke Organization.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - The 2017 update of The Canadian Stroke Best Practice Recommendations for the Secondary Prevention of Stroke is a collection of current evidence-based recommendations intended for use by clinicians across a wide range of settings. The goal is to provide guidance for the prevention of ischemic stroke recurrence through the identification and management of modifiable vascular risk factors. Recommendations include those related to diagnostic testing, diet and lifestyle, smoking, hypertension, hyperlipidemia, diabetes, antiplatelet and anticoagulant therapies, carotid artery disease, atrial fibrillation, and other cardiac conditions. Notable changes in this sixth edition include the development of core elements for delivering secondary stroke prevention services, the addition of a section on cervical artery dissection, new recommendations regarding the management of patent foramen ovale, and the removal of the recommendations on management of sleep apnea. The Canadian Stroke Best Practice Recommendations include a range of supporting materials such as implementation resources to facilitate the adoption of evidence to practice, and related performance measures to enable monitoring of uptake and effectiveness of the recommendations. The guidelines further emphasize the need for a systems approach to stroke care, involving an interprofessional team, with access to specialists regardless of patient location, and the need to overcome geographic barriers to ensure equity in access within a universal health care system.

AB - The 2017 update of The Canadian Stroke Best Practice Recommendations for the Secondary Prevention of Stroke is a collection of current evidence-based recommendations intended for use by clinicians across a wide range of settings. The goal is to provide guidance for the prevention of ischemic stroke recurrence through the identification and management of modifiable vascular risk factors. Recommendations include those related to diagnostic testing, diet and lifestyle, smoking, hypertension, hyperlipidemia, diabetes, antiplatelet and anticoagulant therapies, carotid artery disease, atrial fibrillation, and other cardiac conditions. Notable changes in this sixth edition include the development of core elements for delivering secondary stroke prevention services, the addition of a section on cervical artery dissection, new recommendations regarding the management of patent foramen ovale, and the removal of the recommendations on management of sleep apnea. The Canadian Stroke Best Practice Recommendations include a range of supporting materials such as implementation resources to facilitate the adoption of evidence to practice, and related performance measures to enable monitoring of uptake and effectiveness of the recommendations. The guidelines further emphasize the need for a systems approach to stroke care, involving an interprofessional team, with access to specialists regardless of patient location, and the need to overcome geographic barriers to ensure equity in access within a universal health care system.

UR - http://www.scopus.com/inward/record.url?scp=85041920866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041920866&partnerID=8YFLogxK

U2 - 10.1177/1747493017743062

DO - 10.1177/1747493017743062

M3 - Article

C2 - 29171361

AN - SCOPUS:85041920866

SN - 1747-4930

VL - 13

SP - 420

EP - 443

JO - International Journal of Stroke

JF - International Journal of Stroke

IS - 4

ER -

Canadian stroke best practice recommendations: Secondary prevention of stroke, sixth edition practice guidelines, update 2017

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto